...

Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GET IN TOUCH
Home Small Molecules Discovery Biology Integrated In Vivo Pharmacology Infectitious Diseases

Infectitious Diseases

 Bacterial, viral, fungal, and parasitic infection models. Efficacy testing, pharmacokinetics, biomarker validation, and regulatory-ready efficacy data for antimicrobial and antiviral therapeutics

Aragen’s infectious disease portfolio provides clinically relevant in vivo models for developing antibacterial, antifungal, antiviral, and antiparasitic therapeutics. Our team combines advanced microbiology expertise with sophisticated in vivo pharmacology capabilities to generate predictive efficacy data

Key Model Categories

  • Bacterial infection models (sepsis, pneumonia, wound infection, UTI)
  • Viral infection models (COVID-19, RSV, influenza, HSV)
  • Fungal infection models (candidiasis, aspergillosis, cryptococcosis)
  • Parasitic infection models (malaria, schistosomiasis, hookworm)

Advanced Capabilities

  • Biofilm formation and resistance testing
  • Bacterial persistence and relapse assessment
  • Viral load reduction and clearance
  • Host immune response profiling
  • Antimicrobial stewardship readouts
  • Pharmacokinetic/pharmacodynamic (PK/PD) modeling
  • BSL-2 and BSL-3 containment facilities
Seraphinite AcceleratorOptimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.